drugset / Trial / NCT04923048
A Safety, Tolerability, Pharmacokinetics and Efficacy Study of GB261 in B-Cell NHL and CLL.
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase 1/2 study of GB261 in participants with relapsed or refractory B-cell NHL and CLL. The study will consist of a dose-escalation stage(Phase 1), an expansion stage(Phase 2a) and Phase 2b stage where participants will be enrolled into indication-specific cohorts.
Timeline
- Start
- 2021-08-31
- Primary completion
- 2024-06-28
- Completion
- 2025-06-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GB261 | Protein / enzyme biologic | — | Intravenous |